| s-RSV (n = 199) | s-HRV (n = 47) | Co-infection (n = 73) | P |
---|---|---|---|---|
Age (yr)(\( \overline{X}\pm S \)) | 0.46 ± 0.56d | 0.80 ± 0.78d | 0.53 ± 0.47 | 0.021* |
Gender | ||||
 M n(%) | 137 (68.84) | 38 (80.85) | 56 (76.71) | 0.164 |
 F n(%) | 62 (31.16) | 9 (19.15) | 17 (23.29) |  |
Temperature (°C)(\( \overline{X}\pm S \)) | 37.94 ± 0.75 | 38.10 ± 0.85 | 37.55 ± 4.52 | 0.349 |
Wheezing n(%) | 112 (56.28) | 28 (59.57) | 47 (64.38) | 0.480 |
Lung infiltrates n(%) | 134 (67.34) | 35 (74.47) | 47 (64.38) | 0.506 |
WBC(*109) (\( \overline{X}\pm S \)) | 9.59 ± 5.04 | 9.89 ± 5.11 | 9.44 ± 4.60 | 0.889 |
PMN(*109) (\( \overline{X}\pm S \)) | 35.73 ± 15.38 | 38.50 ± 17.96 | 35.16 ± 18.54 | 0.526 |
EOS(*109) (\( \overline{X}\pm S \)) | 0.26 ± 0.30 | 0.25 ± 0.20 | 0.30 ± 0.46 | 0.561 |
CRPb | 31/195c | 5/47 | 4/71c | 0.076 |
Complications | ||||
 Liver damage n(%) | 38 (19.10) | 5 (10.64) | 11 (15.07) | 0.338 |
 Myocardial damage n(%) | 69 (34.67) | 11 (23.40) | 29 (39.73) | 0.179 |
 Respiratory failure n(%) | 50 (25.13) | 5 (10.64) | 5 (6.85) | < 0.001* |
 Heart failure n(%) | 25 (12.63) | 1 (2.13) | 8 (10.96) | 0.111 |
Oxygen therapyan(%) | 148 (74.37) | 22 (46.81) | 50 (68.49) | 0.001* |
NCPAP n(%) | 50 (25.13) | 5 (10.64) | 6 (8.22) | 0.002* |
Clinical scoree (\( \overline{X}\pm S \)) | 4.10 ± 2.32d | 3.13 ± 1.65d | 3.25 ± 1.47d | < 0.001* |
Bronchiolitis n(%) | 39 (19.60) | 4 (8.51) | 18 (24.66) | 0.086 |
Pneumonia n(%) | 155 (77.89) | 40 (85.11) | 53 (72.60) | 0.274 |
Bronchitis n(%) | 5 (2.51) | 3 (6.38) | 2 (2.74) | 0.365 |